newsfilter
← Latest News
Business Wire·

Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

– Biomarker results indicate GEM103's ability to regulate complement and complement factor H therapeutic approach in geographic atrophy – – GEM103 continues to be well-tolerated and demonstrates a differentiated safety profile with no increased